Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 1 mg, 2 mg) |
| Drug Class | Serotonin-4 receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of chronic idiopathic constipation (CIC) in adults.
Summary
- Prucalopride (Motegrity) is used for the treatment of chronic idiopathic constipation (CIC) in adults.
- A total of 6 systematic reviews/meta-analyses were reviewed to gather information about this drug.
- In a network meta-analysis, prucalopride was found to be more likely associated with adverse events than placebo when treating gastroparesis symptoms, although it did not rank first in efficacy compared to other drugs such as clebopride and domperidone.
- Another study concluded that starting with a 1mg dose of prucalopride could be safer for treating CIC while a 2mg dose might provide better results in terms of spontaneous bowel movements per week outcome receiving; however, higher doses like 2mg and 4mg were significantly associated with more treatment-emergent adverse events.
- When combined with bowel preparation solution at lower volumes for colonoscopy procedures, prucalopride showed similar effects on bowel preparation without increasing the occurrence of adverse effects according to one review.
- Despite its effectiveness over placebo across multiple studies, long-term relative efficacy remains unknown due to most trials having short durations between four and twelve weeks; further research may be needed especially considering safety concerns raised by some studies regarding increased risk for certain side-effects at higher doses or specific uses outside its primary indication area like gastroparesis symptom management or colonoscopy prep assistance where alternatives ranked better overall based on available data.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Motegrity (prucalopride) Prescribing Information. | 2020 | Takeda Pharmaceuticals America, Inc. Lexington, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and safety of drugs for gastroparesis: systematic review and network meta-analysis. | 2023 | Gastroenterology |
| Pharmacological management of neurogenic bowel dysfunction after spinal cord injury and multiple sclerosis: a systematic review and clinical implications. | 2021 | Journal of Clinical Medicine |
| Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and Bayesian analysis. | 2021 | BMJ Open |
| Medical management of constipation in elderly patients: systematic review. | 2021 | Journal of Neurogastroenterology and Motility |
| Efficacy and tolerability of prucalopride in bowel preparation for colonoscopy: a systematic review and meta-analysis. | 2020 | Advances in Therapy |
| Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. | 2019 | The Lancet Gastroenterology & Hepatology |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| American gastroenterological association-american college of gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. | 2023 | Gastroenterology |
| European society of neurogastroenterology and motility guidelines on functional constipation in adults. | 2019 | Neurogastroenterology & Motility |
| Clinical practice guidelines from the French National Society of Coloproctology in treating chronic constipation. | 2018 | European Journal of Gastroenterology & Hepatology |